Literature DB >> 29674499

True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis.

Avinainder Singh1, Hallie I Geller1, Kevin M Alexander1, Robert F Padera2, Richard N Mitchell2, Sharmila Dorbala1, Jorge J Castillo3, Rodney H Falk4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29674499      PMCID： PMC6068030          DOI： 10.3324/haematol.2018.190405

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; Meletios A Dimopoulos
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

3.  Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis.

Authors:  Akihiro Yanagisawa; Mitsuharu Ueda; Takanao Sueyoshi; Tatsuya Okada; Toru Fujimoto; Yasuhiro Ogi; Keisuke Kitagawa; Masayoshi Tasaki; Yohei Misumi; Toshinori Oshima; Hirofumi Jono; Konen Obayashi; Kei Hirakawa; Hitoshi Uchida; Per Westermark; Yukio Ando; Hiroshi Mizuta
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

4.  Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.

Authors:  Hallie I Geller; Avinainder Singh; Tara M Mirto; Robert Padera; Richard Mitchell; Jacob P Laubach; Rodney H Falk
Journal:  Mayo Clin Proc       Date:  2017-12       Impact factor: 7.616

5.  Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.

Authors:  Hallie I Geller; Avinainder Singh; Kevin M Alexander; Tara M Mirto; Rodney H Falk
Journal:  JAMA       Date:  2017-09-12       Impact factor: 56.272

Review 6.  Myeloma and race: a review of the literature.

Authors:  Michael Benjamin; Sreekanth Reddy; Otis W Brawley
Journal:  Cancer Metastasis Rev       Date:  2003-03       Impact factor: 9.264

7.  Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.

Authors:  M A Gertz; R A Kyle; P Noel
Journal:  J Clin Oncol       Date:  1993-05       Impact factor: 44.544

8.  The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.

Authors:  Benjamin Terrier; Arnaud Jaccard; Jean-Luc Harousseau; Richard Delarue; Olivier Tournilhac; Mathilde Hunault-Berger; Mohamed Hamidou; Jacques Dantal; Marc Bernard; Bernard Grosbois; Pierre Morel; Valérie Coiteux; Olivier Gisserot; Philippe Rodon; Arnaud Hot; Caroline Elie; Véronique Leblond; Jean-Paul Fermand; Fadi Fakhouri
Journal:  Medicine (Baltimore)       Date:  2008-03       Impact factor: 1.889

Review 9.  Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-07

10.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983
View more
  1 in total

Review 1.  Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.

Authors:  Vasiliki Bistola; John Parissis; Emmanouil Foukarakis; Pipitsa N Valsamaki; Aris Anastasakis; Georgios Koutsis; Georgios Efthimiadis; Efstathios Kastritis
Journal:  Heart Fail Rev       Date:  2021-01-15       Impact factor: 4.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.